Last reviewed · How we verify
Placebo(for Risedronate)
Placebo does not have a known mechanism of action as it is an inactive substance.
Placebo does not have a known mechanism of action as it is an inactive substance. Used for Osteoporosis prevention in postmenopausal women.
At a glance
| Generic name | Placebo(for Risedronate) |
|---|---|
| Also known as | once a month |
| Sponsor | Hanlim Pharm. Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo is used as a control in clinical trials to compare the efficacy of active treatments. It does not have any therapeutic effect and is not intended to treat any medical condition.
Approved indications
- Osteoporosis prevention in postmenopausal women
Common side effects
- Injection site reaction
- Nausea
- Headache
Key clinical trials
- A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211) (PHASE3)
- Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT (PHASE2)
- Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone (PHASE2, PHASE3)
- Weight Loss With Risedronate for Bone Health (PHASE4)
- A Study of Actonel for the Prevention of Bone Loss (PHASE3)
- IGF-1 and Bone Loss in Women With Anorexia Nervosa (NA)
- VERtebral Fracture Treatment Comparisons in Osteoporotic Women (PHASE4)
- Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant Recipients. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |